Mountain-Cultivated Ginseng Attenuates Phencyclidine-Induced Abnormal Behaviors in Mice by Positive Modulation of Glutathione in the Prefrontal Cortex of Mice.
The-Vinh Tran, Eun-Joo Shin, Sung Kwon Ko, Yunsung Nam, Yoon Hee Chung, Ji Hoon Jeong, Choon-Gon Jang, Seung-Yeol Nah, Kiyofumi Yamada, Toshitaka Nabeshima, Jae Kyung Byun, Hyoung-Chun Kim
Journal of medicinal food October 1, 2016 DOI: 10.1089/jmf.2016.3751 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal study Peer reviewed |
|---|---|
| Population | Mice |
| Interventions | Mountain-cultivated ginseng (MG) Clozapine |
| Dose | MG 200 mg/kg i.p./day; Clozapine 10 mg/kg p.o./day |
| Duration | 14-day PCP treatment, 7-day withdrawal, 7-day MG or clozapine treatment |
| Key points | Mountain-cultivated ginseng ameliorates PCP-induced schizophrenia-like psychosis in mice through positive modulation of the glutathione system. |
Abstract
Escalating evidence indicates that ginseng treatment protects against psychotoxic behaviors and memory impairment. Although the underlying mechanism of schizophrenia remains elusive, recent investigations proposed that downregulation of glutathione (GSH) can be involved in the pathogenesis of this disorder. Since little is known about the effects of ginseng in a schizophrenia-like animal model, we selected mountain-cultivated ginseng (MG) from a variety of ginseng extracts to investigate the effect of ginseng on the psychosis induced by phencyclidine (PCP) in mice. PCP (10 mg/kg/day, s.c.) was administered for 14 consecutive days. Novel object recognition, forced swimming, and social interaction tests were performed during the withdrawal period of 7 days. In addition, behavioral sensitization to an acute challenge of PCP was evaluated. The parameters of the GSH-dependent system in the prefrontal cortex (PFC) were examined. MG (200 mg/kg, i.p./day) or antipsychotic clozapine (10 mg/kg, p.o./day) was administered for seven consecutive days after the final PCP treatment. PCP significantly produced abnormal behaviors, followed by increases in Nrf2 nuclear translocation, its DNA binding activity, and glutamate-cysteine ligase (GCL) mRNA expression in the PFC. PCP treatment significantly decreased GSH/glutathione disulfide (GSSG) ratio and glutathione peroxidase (GPx) activity. MG significantly attenuated abnormal behaviors and the decreases in GSH/GSSG ratio and GPx activity induced by PCP. MG attenuated the increases in Nrf2 activity and GCL expression caused by PCP. The protective potentials of MG were comparable to those of clozapine. MG ameliorates PCP-induced schizophrenia-like psychosis in mice through the positive modulation of the glutathione system.
Citations in the library
Cites 5
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- The role of the hippocampo-prefrontal cortex system in phencyclidine-induced psychosis: a model for schizophrenia. Journal of physiology, Paris December 1, 2013
- Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. British Journal of Pharmacology March 2008
- Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochemistry International 2007
- Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine. Annals of the New York Academy of Sciences November 1, 2006